Discover Why Our Data is BETTER.

A robust set of data available for building prediction models:

1,800

Ticker Symbols

Years of Data

Solutions We Provide:



A radically new competitive intelligence tool that cuts through data noise



GCT

Access to our free, real-time database of more than 600,000+ clinical trial records

AI and machine learning to enhance and refine clinical trial data so you can plan, prepare, and invest in high-risk environments.



Discover drugs in development by disease. mechanism of action, or by country



KRYSTL

Complete market scans across patents, white papers, clinical activity, and news



PRYZM

Trusted sources for pre-clinical, clinical, or approved products



Disease Areas

Data Elements 600k

Clinical Trials

Announcements + White Papers



CONSLT

Expert data analysis and reliable forecasting



We're changing how the healthcare industry works.

Welcome to OZMOSI - a next-generation data and analytics company dedicated to supporting any client investing in the healthcare industry. We're one of the first to automate clinical trial data collection, and meaningfully incorporate AI and machine learning into data refinement, categorization, and predictions from clinical trial data.

About Us

OZMOSI was founded on the idea that today's healthcare data can be better accessed, understood, and leveraged. We believe analytics—based on big data or small data—can support better business decisions.

Contact us for a data trial

See what you can do with clinical trial data.



www.ozmosi.com

600 Warren Ave | Spring Lake NJ USA 07762. +1 732 701 7807 Email: info@ozmosi.com





Intuitive Visuals | Dynamic Views | Custom Reporting

Track Company Strength by Disease Area

Applying BEAM value index and risk adjustment you can easily summarize and visualize any group of companies and their current pipeline by disease area or stage of development.

Compare data from one time period to the next to identify trends or apply this data to identify the best small to mid-sized M&A matches.

	Ove	ouc ouc	Ogé.	HO. Aut	oin. Auto	Jim. Derr	us. Ouc	910	
Hoffmann-La Roche	794	239	45	16	227	0	89		
Bristol-Myers Squibb	512		115	102	49	58	60		- 800
Merck	922	117	2	3	0	2	30		
AstraZeneca	773	57	82	60	0	53	17		
Novartis	507	150	0	73	140	39	27		- 600
Johnson & Johnson	336	163	170	106	31	19	14		
Sanofi	138	58	9	57	147	59	33		- 400
Pfizer	356	43	73	52	0	46	0		100
AbbVie	80	153	105	18	0	56	1		
Regeneron	402	67	0	0	0	0	22		- 200
Incyte	248	46	0	0	0	88	6		
Amgen	172	122	10	19	0	65	13		- 0



Product Discovery | Tracking | Probability of Success

Track Predictions for Clinical Readouts

Autoimmune Diseases

Clinical outcomes are one the most common drivers of value shifts in the pharmaceutical and biotech marketplace. Now you can have all the predicted announcement dates and probability of success at your fingertips.




NEW

Next-Gen Probability of Success for Each Development Stage

Our NEW probability of success measure is uncovering multiple industry trends that were never before available.

Contact us today to learn more about how our success predictions are delivering accuracy of 70%-80%.

www.ozmosi.com



Late Stage Development

Variable Success Factors Per Trial Stage

TAKEAWAYS:

In the early stage of development, Clinical Trial Design best supports predictions of success.

In late stage, the impact of the specific Disease Area is nominal while Company Experience and especially Treatment Attributes become more important to predicting success.